IL-6反式信号促进CAR T细胞扩增与抗肿瘤活性
该研究探讨IL-6反式信号在CAR T细胞中的作用,通过构建表达HIL-6或组成型活性GP130的CAR T细胞,在体外和异种移植模型中评估其增殖与抗肿瘤效果。结果显示HIL-6 CAR T细胞增强增殖和抗肿瘤活性但诱发严重GVHD,而表达组成型活性GP130的CAR T细胞保留抗肿瘤活性且无GVHD迹象。
要点
- HIL-6 CAR T细胞增强增殖和抗肿瘤效果但导致严重GVHD。
- 组成型活性GP130 CAR T细胞保留抗肿瘤活性且无GVHD迹象。
- IL-6反式信号通过GP130/STAT3通路增强CAR T细胞功能。
核心结论
- IL-6反式信号可通过GP130/STAT3通路增强CAR T细胞的扩增和抗肿瘤活性。
- 在CAR T细胞内表达GP130可能提高抗肿瘤疗效而不引起系统性IL-6反式信号。
研究设计与样本
- 研究构建了组成型表达HIL-6或组成型活性GP130的CAR T细胞。
- 在体外和异种移植模型中评估CAR T细胞的功能。
- 进行了转录组分析。
主要发现
- HIL-6 CAR T细胞在体外和异种移植模型中表现出增强的增殖和抗肿瘤效果。
- HIL-6 CAR T细胞引起严重GVHD。
- HIL-6刺激CAR T细胞上调与T细胞迁移、早期记忆分化和IL-6/GP130/STAT3信号相关的基因。
- 表达组成型活性GP130的CAR T细胞在B细胞白血病和实体瘤临床前模型中保留改善的抗肿瘤活性且无GVHD迹象。
临床怎么用
- CAR T细胞中表达GP130可能作为一种策略增强抗肿瘤效果并避免系统性IL-6反式信号相关毒性。
局限性
- 研究主要基于体外和异种移植模型,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within CAR T-cells has not been reported. We generated CAR T cells that constitutively express hyper IL-6 (HIL-6), a designer cytokine that activates the trans-signaling pathway. HIL-6-expressing CAR T-cells exhibited enhanced proliferation and antitumor efficacy in vitro and in xenograft models. However, HIL-6 CAR T cells caused severe graft-versus-host disease (GVHD). Transcriptomic profiling revealed that HIL-6 stimulation of CAR T cells upregulated genes associated with T cell migration, early memory differentiation, and IL-6/GP130/STAT3 signaling. Since IL-6 trans-signaling acts via surface GP130, we generated CAR T cells expressing a constitutively-active form of GP130 and found these retained improved antitumor activity without signs of GVHD in preclinical models of B-cell leukemia and solid tumors. Taken together, these results show that IL-6 trans-signaling can enhance expansion and antitumor activity of CAR T cells via the GP130/STAT3 pathway, and suggest that expression of GP130 within CAR T cells could lead to improved antitumor efficacy without systemic IL-6 trans-signaling.
引用
- Jiang Z, Liao R, Lv J, et al. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2020. PMID: 33168950. doi:10.1038/s41375-020-01085-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。